Laboratory services company Labcorp has accelerated a strategy to drive growth through a string of healthcare system acquisitions and partnerships as its COVID PCR testing volumes have tapered off.

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has completed the acquisition of CorEvitas, LLC (“CorEvitas”), a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity (“Audax”), for $912.5 million in cash. Thermo Fisher announced the agreement to acquire CorEvitas on July 6, 2023.

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. ( “Mindray”) has agreed to acquire 75% equity interest in DiaSys Diagnostic Systems GmbH (“DiaSys”) from Gorka Holding GmbH, through Mindray Medical Netherlands B.V. (“Mindray Netherlands”), a wholly-owned subsidiary of Mindray’s wholly-owned subsidiary MR Global (HK) Limited, for an all-cash preliminary purchase price of approx. €115 million.

Fortis Life Sciences on Wednesday said it has acquired diagnostic testing component maker International Point of Care.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that it has entered into an agreement with Legacy Health to acquire select assets of its outreach laboratory business, including laboratory facilities and equipment. Labcorp will also manage Legacy's inpatient hospital laboratories through a long-term agreement to provide staffing, leadership, scientific knowledge, analytics, supply chain services and laboratory support.

Diagnostics company Novacyt UK has agreed to purchase UK-based genomic medicine company Yourgene Health in a £16.7m ($21.3m) deal.

Thermo Fisher Scientific (TMO.N) said on Thursday it would acquire healthcare data provider CorEvitas for $912.5 million in cash, as the medical products maker looks to boost its portfolio of services offered to pharmaceutical clients.

Recently, Shanghai BioGerm Medical Technology Co., Ltd. reached a strategic consensus and completed the signing of a contract, in which BioGerm will formally enter the biochemical diagnostic field by wholly acquiring Kaisheng Biology.

Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases.

Bio-Techne announced on Thursday that it is acquiring Swiss spatial biology firm Lunaphore for an undisclosed amount.